Kyowa Kirin Co., Ltd.
Stock Price Chart
2026/08/21 UpdatedPrice Trend
2026/08/21 UpdatedPrice & Trading Details
2026/08/21 UpdatedPRICE
TRADING
Analyst Recommendations 11 analysts
Updated 2026/08/01Earnings Calendar
Updated 2026/08/01Recent Earnings
| Date | EPS Est. | EPS Actual | Surprise |
|---|---|---|---|
| 2026/05/06 | ¥27.46 | ¥22.99 | -16.3% |
| 2026/02/08 | ¥37.60 | ¥65.79 | +75.0% |
| 2025/10/29 | ¥28.91 | ¥31.10 | +7.6% |
| 2025/07/30 | ¥31.83 | ¥19.40 | -39.1% |
Shareholder Composition
Updated 2026/08/01Top Mutual Funds / ETFs
Updated 2026/08/01Major Holders
Updated 2026/08/01| Fund Name | Ownership | Shares | Change |
|---|---|---|---|
|
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund
|
3.5M | +0.05% | |
|
VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund
|
2.3M | +2.58% | |
|
iShares Trust-iShares Core MSCI EAFE ETF
|
1.7M | 0.00% | |
|
iShares, Inc.-iShares MSCI Japan ETF
|
1.0M | +4.21% | |
|
iShares Trust-iShares MSCI EAFE Min Vol Factor ETF
|
995.0K | -2.13% | |
|
Fidelity Concord Street Trust-Fidelity International Index Fund
|
910.6K | +2.27% |
| Institution | Ownership | Shares | Change |
|---|---|---|---|
|
Pacer Advisors, Inc.
|
1.9K | +2.91% |
Dividend History
Updated 2026/08/23| Year | Dividend | Change |
|---|---|---|
| 2026 | ¥35 | -43.5% |
| 2025 | ¥62 | +6.9% |
| 2024 | ¥58 | +3.6% |
| 2023 | ¥56 | +9.8% |
| 2022 | ¥51 | - |
Financial Performance
2026/08/23 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥352,246M | ¥398,371M | ¥442,233M | ¥495,558M |
| Gross Profit | ¥264,398M | ¥311,455M | ¥331,026M | ¥362,947M |
| Operating Income | ¥61,111M | ¥82,374M | ¥95,842M | ¥91,866M |
| Pretax Income | ¥61,167M | ¥68,660M | ¥97,436M | ¥90,991M |
| Net Income | ¥52,347M | ¥53,573M | ¥81,188M | ¥59,870M |
| EPS | ¥97.39 | ¥99.66 | ¥151.01 | ¥113.06 |
| Operating Margin | 17.35% | 20.68% | 21.67% | 18.54% |
| Balance Sheet | ||||
| Total Assets | ¥921,872M | ¥939,881M | ¥1,025,942M | ¥1,067,363M |
| Total Equity | ¥737,162M | ¥762,826M | ¥836,418M | ¥850,811M |
| Total Liabilities | ¥184,710M | ¥177,055M | ¥189,524M | ¥216,552M |
| Cash | ¥335,084M | ¥339,194M | ¥403,083M | ¥244,681M |
| Interest-bearing Debt | - | - | - | - |
| Equity Ratio | 79.96% | 81.16% | 81.53% | 79.71% |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow | ||||
| Operating CF | ¥86,546M | ¥48,672M | ¥115,552M | ¥67,884M |
| Investing CF | -¥11,362M | -¥17,185M | -¥20,381M | -¥142,389M |
| Financing CF | -¥28,446M | -¥29,032M | -¥32,535M | -¥84,697M |
| Free CF | ¥66,780M | ¥20,006M | ¥82,700M | -¥37,384M |
| Efficiency | ||||
| ROE | 7.10% | 7.02% | 9.71% | 7.04% |
| ROA | 5.68% | 5.70% | 7.91% | 5.61% |
Latest IR Information
-
Financial Summary Supplement — Interim Financial Results for the Fiscal Year Ending December 2026, Q2
Discloses consolidated performance and cash flow trends for the second quarter of the fiscal year ending December 2026. Revenue by region and by product is shown, along with trends in core operating margin and R&D intensity. Forward guidance is provided...
Read more -
Kowa Kirin Co., Ltd. 2026 Fiscal Year December Interim (Six-Month) Financial Summary [IFRS] (Consolidated)
The consolidated results for the second half of the 2026 fiscal year (six months) disclose trends in revenue and profit. The financial position including changes in non-current and current assets, liabilities, and capital structure is reported, along with regional revenue...
Read more -
Regarding Matters Concerning the Controlling Shareholder
The parent company Kirin Holdings Company, Limited holds 55.22% of the voting rights. Our company maintains management independence while leveraging the Group’s expertise.
Read more -
Notice Regarding Disposal of Treasury Stock as Restricted Stock Compensation and Performance-Linked Stock Compensation
On April 9, 2026, Kyowa Kirin will dispose of 99,648 shares of treasury stock (totaling 240,649,920 yen) as restricted stock compensation and performance-linked stock compensation.
Read more -
(Revised) Partial Correction of “Financial Summary Supplementary Materials - Fiscal Year Ending December 2025 -”
In the supplementary materials for consolidated results for the fiscal year ending December 2025, a correction was made to a calculation error in the consolidated cash flow statement regarding acquisition expenditures for tangible fixed assets. Revenue was 496.8 billion yen,...
Read more -
(Correction: Numerical Data Correction) Partial Correction Regarding the "Financial Summary for the Fiscal Year Ending December 2025 [IFRS] (Consolidated)"
Corrected an error in the calculation of “Payments for acquisition of property, plant and equipment” in the consolidated cash flow statement of the financial summary for the fiscal year ending December 2025, revising cash flows from operating activities from JPY...
Read more
Latest News (5 items)
-
Average Analyst Rating: none
Average Target Price: ¥2,241
Rating Score: 3.45 (Based on 11 analysts)
※1=Strong Buy, 5=Strong Sell
Company Information
About
Kyowa Kirin Co., Ltd. engages in the research, development, manufacturing, and marketing of pharmaceuticals in Japan, the Americas, Europe, Asia, and internationally. The company offers Ziftomenib, an oral menin inhibitor for the treatment of adult relapsed or refractory and acute myeloid leukemia with a nucelophosmin1 mutation; and Lumicef for the treatment of palmoplantar pustulosis. It also develops KHK4083/AMG 451 rocatinlimab, which is in Phase III clinical trial for the treatment of moderate to severe atopic dermatitis and prurigo nodularis; KK8398 infigratinib, which is in Phase III clinical trial for the treatment of achondroplasia; OTL-203, which is in Phase III clinical trial for the treatment of hurler syndrome; KHK4951 tivozanib, which is in Phase II clinical trial for the treatment of diabetic macular edema and neovascular age-related macular degeneration; and OTL-201, which is in Phase II clinical trial for the treatment of sanfilippo syndrome type A. In addition, the company is involved in the development of KK2260 and KK2269, which are both in Phase I clinical trials for the treatment of advanced or metastatic solid tumors; KK2845, which is in Phase I clinical trial for the treatment of acute myeloid leukemia; KK3910, which is in Phase I clinical trial for the treatment of essential hypertension; KK4277, which is in Phase I clinical trial for the treatment of systemic/cutaneous lupus erythematosus; and KK8123, which is in Phase I clinical trial for the treatment of X-linked hypophosphatemia. It has a partnership with La Jolla Institute for Immunology for research in disease areas; AstraZeneca for severe asthma treatment; and AMGEN for therapeutic drugs development. The company was formerly known as Kyowa Hakko Kirin Co., Ltd. and changed its name to Kyowa Kirin Co., Ltd. in July 2019. Kyowa Kirin Co., Ltd. was incorporated in 1949 and is headquartered in Chiyoda, Japan. The company operates as a subsidiary of Kirin Holdings Company, Limited.
